Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon J Draper

Showing results (141-150 of 165) with videos related to

Pageof 17
Sort By:
Nature Communications|November 29, 2013
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisationKatie J Ewer, Geraldine A O'Hara, Christopher J A Duncan, et al.
Frontiers in Immunology|September 8, 2022
Repeat controlled human malaria infection of healthy UK adults with blood-stage <i>Plasmodium falciparum</i>: Safety and parasite growth dynamicsJo Salkeld, Yrene Themistocleous, Jordan R Barrett, et al.
The Journal of Clinical Investigation|February 9, 2022
Streptococcus pneumoniae colonization associates with impaired adaptive immune responses against SARS-CoV-2Elena Mitsi, Jesús Reiné, Britta C Urban, et al.
Plos One|July 30, 2011
Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909Christopher J A Duncan, Susanne H Sheehy, Katie J Ewer, et al.
Immunity|June 12, 2026
Analysis of monoclonal antibodies against the malaria invasion complex protein RIPR reveals the structural basis for synergistic antibody protectionBarnabas G Williams, Jordan R Barrett, Josefin Bartholdson Scott, et al.
The Lancet. Infectious Diseases|December 13, 2024
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in childrenHamtandi M Natama, Jo Salkeld, Athanase Somé, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 24, 2012
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humansSusanne H Sheehy, Christopher J A Duncan, Sean C Elias, et al.
Frontiers in Microbiology|January 8, 2015
Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injectionSusanne H Hodgson, Elizabeth Juma, Amina Salim, et al.
NPJ Vaccines|August 23, 2018
Production, quality control, stability, and potency of cGMP-produced <i>Plasmodium falciparum</i> RH5.1 protein vaccine expressed in <i>Drosophila</i> S2 cellsJing Jin, Richard D Tarrant, Emma J Bolam, et al.
Cell|June 18, 2019
Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing AntibodiesDaniel G W Alanine, Doris Quinkert, Rasika Kumarasingha, et al.
Pageof 17

Showing results (141-150 of 165) with videos related to

Sort By:
Pageof 17
Nature Communications|November 29, 2013
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisationKatie J Ewer, Geraldine A O'Hara, Christopher J A Duncan, et al.
Frontiers in Immunology|September 8, 2022
Repeat controlled human malaria infection of healthy UK adults with blood-stage <i>Plasmodium falciparum</i>: Safety and parasite growth dynamicsJo Salkeld, Yrene Themistocleous, Jordan R Barrett, et al.
The Journal of Clinical Investigation|February 9, 2022
Streptococcus pneumoniae colonization associates with impaired adaptive immune responses against SARS-CoV-2Elena Mitsi, Jesús Reiné, Britta C Urban, et al.
Plos One|July 30, 2011
Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909Christopher J A Duncan, Susanne H Sheehy, Katie J Ewer, et al.
Immunity|June 12, 2026
Analysis of monoclonal antibodies against the malaria invasion complex protein RIPR reveals the structural basis for synergistic antibody protectionBarnabas G Williams, Jordan R Barrett, Josefin Bartholdson Scott, et al.
The Lancet. Infectious Diseases|December 13, 2024
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in childrenHamtandi M Natama, Jo Salkeld, Athanase Somé, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 24, 2012
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humansSusanne H Sheehy, Christopher J A Duncan, Sean C Elias, et al.
Frontiers in Microbiology|January 8, 2015
Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injectionSusanne H Hodgson, Elizabeth Juma, Amina Salim, et al.
NPJ Vaccines|August 23, 2018
Production, quality control, stability, and potency of cGMP-produced <i>Plasmodium falciparum</i> RH5.1 protein vaccine expressed in <i>Drosophila</i> S2 cellsJing Jin, Richard D Tarrant, Emma J Bolam, et al.
Cell|June 18, 2019
Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing AntibodiesDaniel G W Alanine, Doris Quinkert, Rasika Kumarasingha, et al.
Pageof 17